Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S (2012) Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J Affect Disord 141:308–314

Article  CAS  PubMed  Google Scholar 

Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, Mohebbi-Rasa S, Raznahan M, Kamalipour A (2009) Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 26:607–611

Article  CAS  PubMed  Google Scholar 

Arteaga-Henriquez G, Simon MS, Burger B, Weidinger E, Wijkhuijs A, Arolt V, Birkenhager TK, Musil R, Muller N, Drexhage HA (2019) Low-grade inflammation as a predictor of antidepressant and anti-inflammatory therapy response in MDD patients: a systematic review of the literature in combination with an analysis of experimental data collected in the EU-MOODINFLAME consortium. Front Psychiatry 10:458

Article  PubMed  PubMed Central  Google Scholar 

Benedetti F, Poletti S, Hoogenboezem TA, Mazza E, Ambree O, de Wit H, Wijkhuijs AJ, Locatelli C, Bollettini I, Colombo C, Arolt V, Drexhage HA (2016) Inflammatory cytokines influence measures of white matter integrity in bipolar disorder. J Affect Disord 202:1–9

Article  CAS  PubMed  Google Scholar 

Benedetti F, Poletti S, Hoogenboezem TA, Locatelli C, de Wit H, Wijkhuijs AJM, Colombo C, Drexhage HA (2017) Higher baseline proinflammatory cytokines mark poor antidepressant response in bipolar disorder. J Clin Psychiatry 78:e986–e993

Article  PubMed  Google Scholar 

Benedetti F, Aggio V, Pratesi ML, Greco G, Furlan R (2020) Neuroinflammation in bipolar depression. Front Psychiatry 11:71

Article  PubMed  PubMed Central  Google Scholar 

Benedetti F, Mazza M, Cavalli G, Ciceri F, Dagna L, Rovere-Querini P (2021a) Can cytokine blocking prevent depression in COVID-19 survivors?? J Neuroimmune Pharmacol 16:1–3

Article  PubMed  Google Scholar 

Benedetti F, Palladini M, Paolini M, Melloni E, Vai B, De Lorenzo R, Furlan R, Rovere-Querini P, Falini A, Mazza MG (2021b) Brain correlates of depression, post-traumatic distress, and inflammatory biomarkers in COVID-19 survivors: a multimodal magnetic resonance imaging study. Brain Behav Immun 18:100387

CAS  Google Scholar 

Benedetti F, Poletti S, Vai B, Mazza MG, Lorenzi C, Brioschi S, Aggio V, Branchi I, Colombo C, Furlan R, Zanardi R (2021c) Higher baseline interleukin-1beta and TNF-alpha hamper antidepressant response in major depressive disorder. Eur Neuropsychopharmacol 42:35–44

Article  CAS  PubMed  Google Scholar 

Benedetti F, Zanardi R, Mazza MG (2022) Antidepressant psychopharmacology: is inflammation a future target? Int Clin Psychopharmacol 37:79–81

Article  PubMed  Google Scholar 

Bravi B, Bollettini I, Di Pasquasio C, Falini A, Colombo C, Zanardi R, Poletti S, Benedetti F (2022) Brain spectroscopic measures of glutamatergic and neuronal metabolism and glial activation influence white matter integrity in bipolar depression. Psychiatry Res Neuroimaging 326:111534

Article  PubMed  Google Scholar 

Campochiaro C, Della-Torre E, Cavalli G, De Luca G, Ripa M, Boffini N, Tomelleri A, Baldissera E, Rovere-Querini P, Ruggeri A, Monti G, De Cobelli F, Zangrillo A, Tresoldi M, Castagna A, Dagna L, Group T-RS (2020) Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med 76:43–49

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, Oltolini C, Castiglioni B, Din T, Boffini C, Tomelleri N, Farina A, Ruggeri N, Rovere-Querini A, Di Lucca P, Martinenghi G, Scotti S, Tresoldi R, Ciceri M, Landoni F, Zangrillo G, Scarpellini A, Dagna P, L (2020) Interleukin-1 blockade with high-dose Anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol 2:e325–e331

Article  PubMed  PubMed Central  Google Scholar 

Chakravarty R, Jyani G, Paul S, Mohindra R, Goyal M, Suri V, Bhalla A, Singh SM (2023) Depression, anxiety, and quality of life in patients treated with single infusion Tocilizumab for COVID-19: a follow-up, controlled study. Indian J Psychol Med 45:47–52

Article  PubMed  Google Scholar 

da Silva Lopes L, Silva RO, de Sousa Lima G, de Araujo Costa AC, Barros DF, Silva-Neto RP (2021) Is there a common pathophysiological mechanism between COVID-19 and depression? Acta Neurol Belg 121:1117–1122

Article  PubMed  PubMed Central  Google Scholar 

Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9:46–56

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Lorenzo R, Mazza MG, Sciorati C, Leone R, Scavello F, Palladini M, Merolla A, Ciceri F, Bottazzi B, Garlanda C, Benedetti F, Rovere-Querini P, Manfredi AA (2024) Post-COVID trajectory of pentraxin 3 plasma levels over 6 months and their association with the risk of developing post-acute depression and anxiety. CNS Drugs 38:459–472

Article  PubMed  Google Scholar 

De Luca G, Cavalli G, Campochiaro C, Della-Torre E, Angelillo P, Tomelleri A, Boffini N, Tentori S, Mette F, Farina N, Rovere-Querini P, Ruggeri A, D’Aliberti T, Scarpellini P, Landoni G, De Cobelli F, Paolini JF, Zangrillo A, Tresoldi M, Trapnell BC, Ciceri F, Dagna L (2020) GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatol 2:e465–e473

Article  PubMed  PubMed Central  Google Scholar 

Della-Torre E, Campochiaro C, Cavalli G, De Luca G, Napolitano A, La Marca S, Boffini N, Da Prat V, Di Terlizzi G, Lanzillotta M, Rovere Querini P, Ruggeri A, Landoni G, Tresoldi M, Ciceri F, Zangrillo A, De Cobelli F, Dagna L (2020) Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis 79:1277–1285

Article  CAS  PubMed  Google Scholar 

Deng J, Zhou F, Hou W, Silver Z, Wong CY, Chang O, Huang E, Zuo QK (2021) The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: a meta-analysis. Ann N Y Acad Sci 1486:90–111

Article  CAS  PubMed  Google Scholar 

Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctot KL (2010) A meta-analysis of cytokines in major depression. Biol Psychiatry 67:446–457

Article  CAS  PubMed  Google Scholar 

Ellul P, Boyer L, Groc L, Leboyer M, Fond G (2016) Interleukin-1 beta-targeted treatment strategies in inflammatory depression: toward personalized care. Acta Psychiatr Scand 134:469–484

Article  CAS  PubMed  Google Scholar 

Elnazer HY, Sampson AP, Baldwin DS (2021) Effects of celecoxib augmentation of antidepressant or anxiolytic treatment on affective symptoms and inflammatory markers in patients with anxiety disorders: exploratory study. Int Clin Psychopharmacol 36:126–132

Article  PubMed  Google Scholar 

Felger JC, Li Z, Haroon E, Woolwine BJ, Jung MY, Hu X, Miller AH (2016) Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression. Mol Psychiatry 21:1358–1365

Article  CAS  PubMed  Google Scholar 

Fields C, Drye L, Vaidya V, Lyketsos C, Group AR (2012) Celecoxib or naproxen treatment does not benefit depressive symptoms in persons age 70 and older: findings from a randomized controlled trial. Am J Geriatr Psychiatry 20:505–513

Article  PubMed  PubMed Central  Google Scholar 

Green C, Shen X, Stevenson AJ, Conole ELS, Harris MA, Barbu MC, Hawkins EL, Adams MJ, Hillary RF, Lawrie SM, Evans KL, Walker RM, Morris SW, Porteous DJ, Wardlaw JM, Steele JD, Waiter GD, Sandu AL, Campbell A, Marioni RE, Cox SR, Cavanagh J, McIntosh AM, Whalley HC (2021) Structural brain correlates of serum and epigenetic markers of inflammation in major depressive disorder. Brain Behav Immun 92:39–48

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haroon E, Miller AH (2017) Inflammation effects on glutamate as a pathway to neuroprogression in mood disorders. Mod Trends Pharmacopsychiatry 31:37–55

Article  PubMed  Google Scholar 

Haroon E, Miller AH, Sanacora G (2017) Inflammation, glutamate, and glia: a trio of trouble in mood disorders. Neuropsychopharmacology 42:193–215

Article  CAS  PubMed  Google Scholar 

Hayes AF (2017) Introduction to mediation, moderation, and conditional process analysis: a regression-based approach. Guilford Publications, New York

Hodes GE, Kana V, Menard C, Merad M, Russo SJ (2015) Neuroimmune mechanisms of depression. Nat Neurosci 18:1386–1393

Article  CAS  PubMed